>
Home > Trending on TAP > November 2018 > Bifidobacterium breve B-3 Reduces Body Fat in Obese Subjects

Bifidobacterium breve B-3 Reduces Body Fat in Obese Subjects

11/28/2018 5:03:34 PM
The composition of gut microbiota is emerging as a risk factor for obesity, with studies reporting lower levels of Bifidobacterium and higher levels of Firmicutes in obese subjects than in lean subjects. Higher levels of the lipopolysaccharide (LPS)-binding protein have been detected in overweight and obese individuals, suggesting that intestinal permeability, subclinical endotoxemia, and low-grade inflammation mechanistically link changes in the gut microbiome to changes in metabolism and body weight.
 
Bifidobacterium breve B-3 has been shown to reduce body fat mass in humans with metabolic diseases, with a previous meta-analysis indicating that it reduced fat mass by 0.7 kg over 12 weeks at a dosage of 50 billion CFU/day. In the current study, researchers evaluated the effect of Bifidobacterium breve B-3 in overweight subjects without diabetes, hypertension, hyperlipidemia, or any other disorders.
 
A total of 80 healthy subjects were randomized to take a placebo or Bifidobacterium breve B-3 (20 billion CFU/day) for 12 weeks. There were no significant differences in dietary constituents between the groups, and participants were advised to continue their regular exercise routines. The primary outcome measure was the change in abdominal visceral fat after 12 weeks.
 
Results indicated no significant changes in the primary outcome measure of abdominal visceral fat at 12 weeks, but some secondary measures reached significance. Percent body fat and body fat mass were significantly lower in the B-3 group than in the placebo group at week 12. The between-group difference in percent body fat at the end of the study was 0.7%, and the between-group difference in body fat mass was 0.6 kg. Waist circumference was significantly lower at week 12 than at baseline in the B-3 group only. No significant differences were detected in blood parameters (including markers of inflammation, blood sugar regulation, and lipid metabolism), but triglyceride levels decreased slightly, and HDL-cholesterol increased slightly from baseline in the B-3 group.     
 
The results of this randomized, placebo-controlled trial suggest promise for the role of Bifidobacterium breve B-3 in reducing body fat in overweight individuals with no adverse effects.
 
Reference
Minami J, Iwabuchi N, Tanaka M et al. Effects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: a randomized, double-blind, placebo-controlled trial. Biosci Microbiota Food Health. 2018; 37: 67-75.

Have Clinical Research Summaries Delivered to Your Inbox
TAP Integrative is your go-to resource for integrative clinical protocols, case studies, and evidence-based clinical information. Sign up for TAP’s enewsletter and receive integrative clinical research summaries, clinical pearls and tips from integrative experts delivered straight to your inbox. Bonus: Receive TAP’s top 3 patient education downloads FREE. Subscribe here >>>